Gates urges investment in innovations for developing nations
January 25, 2012Research and Development AIDS, Bill Gates, Global Fund, TB, malaria
Bill Gates has called on global leaders to invest in innovations that are accelerating progress against poverty, or risk a …
Councils given £2.2 billion for public health
January 25, 2012Research and Development, Sales and Marketing Lansley, NHS, public health outcomes framework
The government’s new vision for public health has come under fire from observers worried that accountability for the strategy remains …
MHRA Inspections of CROs
January 24, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Audits, Wainwright Associates, inspectons
In accordance with the provisions of the new pharmacovigilance legislation, as per Directive 2010/84/EU, EU Competent Authorities may inspect the …
Moving towards milestones: the evolving pharma – biotech relationship
January 24, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Deals, Susan Aldridge, biotech, pharma
Big pharma is going through the greatest ever wave of patent expiries, while small biotechs are finding it hard to …
Richard Barker elected to Celgene’s board of directors
January 24, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Celgene, Richard Barker
Celgene, the biopharma firm specialising in cancer and inflammatory diseases, has elected Richard Barker to its board of directors. Dr …
Genzyme’s Framingham site cleared by FDA
January 24, 2012Manufacturing and Production FDA, Fabrazyme, Fabry, Genzyme
The FDA has cleared Genzyme to begin production of Fabrazyme at its new manufacturing site. The approval of the new …
Patheon gets bigger in softgels with Procaps alliance
January 24, 2012Manufacturing and Production Patheon, Procaps, manufacturing
Contract development and manufacturing organisation Patheon has stepped up its position in the market for pharmaceutical capsules with the signing …
Alnylam cuts workforce by a third
January 23, 2012Research and Development, Sales and Marketing Alnylam, Novartis, job cuts, rnai
Alnylam will cut 33% of its workforce this year as it looks to focus on developing its own products. The …
MPs to criticise NHS reforms
January 23, 2012Sales and Marketing Clegg, Dorrell, NHS reform, health bill
Reform of the NHS is risking its financial stability and the care of the elderly, according to MPs. The concerns …
Carbogen Amcis buys French CRO
January 23, 2012Manufacturing and Production Carbogen Amcis, Creapharm Parenterals
Swiss contract manufacturing organisation Carbogen Amcis has acquired a contract manufacturer based in France – Creapharm Parenterals – to bolster …
Contract research news in brief
January 23, 2012Research and Development CoreLab Partners and Acurian, Quintiles, vivoPharma
Quintiles invests in new biomarket firm and sets up a new office in China, plus updates from vivoPharma, CoreLab Partners …
Merck pays $37m to settle Canadian Vioxx claims
January 23, 2012Sales and Marketing Canada, Merck, Vioxx
Merck will pay a maximum of C$37 million to settle all claims against its painkiller Vioxx in Canada. The settlement …
Genzyme lifted by EU approval of Fabrazyme facility
January 20, 2012Manufacturing and Production Boston, EMA, Fabrazyme, Genzyme
Sanofi subsidiary Genzyme moved a crucial step closer to resolving its long-standing manufacturing problems after the European Medicines Agency gave …
Payment changes of authority’s fees in France
January 20, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates, regulatory affairs
Changes are being made in the way fees are paid for regulatory submissions and procedures in France. Fees are no …
Novartis’ Signifor recommended in Europe
January 20, 2012Research and Development, Sales and Marketing CHMP, Cushing's disease, Novartis, Signifor
A European committee has recommended Novartis’ Signifor for the treatment of a rare, debilitating endocrine disorder. The European Committee for …
EMA to review safety of MS drug Gilenya
January 20, 2012Research and Development, Sales and Marketing CHMP, EMA, Novartis, gilenya
The European Medicines Agency has begun a review into the safety of Novartis’ multiple sclerosis drug Gilenya. This follows concerns …
British pharmacy to sell ‘smart pills’
January 20, 2012Sales and Marketing Lloyds pharmacy, Proteus Biomedical, smart pill
Proteus Biomedical has teamed up with Lloydspharmacy to sell Helius, a smart pill that tells a patient when to take …
AZ and BMS diabetes drug needs more data
January 20, 2012Research and Development, Sales and Marketing AstraZeneca, BMS, FDA approvals, diabetes
AstraZeneca and Bristol-Myers Squibb must supply more data on their diabetes treatment dapagliflozin, the FDA says.Currently being developed as monotherapy, …
Novartis starts late-stage biosimilar trials for Amgen drugs
January 19, 2012Research and Development, Sales and Marketing Amgen, Neulasta, Neupogen, Novartis
Novartis has begun Phase III biosimilar trials to copycat two of Amgen’s neutropenia drugs. The studies, which are being undertaken …
Chief operating officer appointed to Clinigen’s services division
January 19, 2012Business Services, Medical Communications, Research and Development, Sales and Marketing Clinigen, Shaun Chilton
Clinigen Group, a global specialty pharma services and products business, has appointed Shaun Chilton as its new chief operating officer …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
